Homogeneous Ophthalmic Composition for Post-Operative Care
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current post-operative medication regimens for cataract surgery are complex and difficult for patients to follow, leading to issues like medication washout, contamination, and increased risk of complications such as cystoid macular edema, due to the need for multiple topical applications of separate antibiotics and anti-inflammatory agents.
Innovation Solution
A single, homogeneous aqueous solution combining moxifloxacin hydrochloride, dexamethasone sodium phosphate, and bromfenac sodium sesquihydrate, with additives like hydroxyethyl cellulose and benzalkonium chloride, is developed to simplify the medication regimen and improve compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple separate topical medications are applied to the eye, then comprehensive treatment coverage is achieved, but patient compliance deteriorates and complexity of operation increases
Solution Approach 1:
The patent combines multiple separate ophthalmic medications (antibiotic, anti-inflammatory, and steroid agents) into a single multi-component ophthalmic solution. This merging approach maintains comprehensive treatment coverage while significantly simplifying the administration process for patients, requiring only one bottle and one application per day instead of multiple separate medications applied multiple times daily.
Solution Approach 2:
The ophthalmic solution is designed as a universal formulation that performs multiple therapeutic functions simultaneously. It contains antibiotic, anti-inflammatory, and steroid components that work together to prevent infection, reduce inflammation, and prevent cystoid macular edema, thereby providing comprehensive post-operative care through a single multi-functional product.
2Reliability
If multiple separate medications are used, then comprehensive treatment is provided, but time consumption increases
Solution Approach 1:
By merging multiple medications into a single solution, the patent eliminates the need for patients to spend time applying multiple separate medications at different times throughout the day. The single combined solution can be applied once daily, dramatically reducing the time commitment required for post-operative care while maintaining comprehensive treatment effectiveness.
3Manufacturing precision
If separate medication bottles are used, then specific dosing control is achieved, but risk of contamination and misplacement increases
Solution Approach 1:
The patent merges multiple medications into a single sterile ophthalmic solution contained in one bottle. This approach eliminates the risks associated with handling multiple separate bottles, including contamination during transfer, misplacement of bottles, and confusion about which medication has been administered. The single-bottle design maintains dosing precision while removing contamination vectors.
4Device complexity
If quinoline antibiotic and anti-inflammatory agent are combined, then simplified formulation is achieved, but precipitate formation occurs
Solution Approach 1:
The patent resolves the precipitate formation issue by carefully controlling the pH of the ophthalmic solution within a specific range (pH 6.5-8.0). This parameter control, combined with selecting specific salt forms of the antibiotics and anti-inflammatory agents, maintains formulation stability and prevents precipitation while achieving the desired simplified combined formulation.
Solution Approach 2:
The patent employs a composite formulation strategy by selecting specific compatible salt forms of antibiotics (such as hydrochloride salts) and anti-inflammatory agents that can coexist in the same aqueous solution without precipitating. This composite approach allows multiple active ingredients to be combined in a single stable formulation.
Data Source
AI summary
This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.